Mind Medicine (MindMed) Inc., a clinical biopharmaceutical company, has appointed Brandi L. Roberts as its new Chief Financial Officer, effective June 2, 2025. Roberts will join the executive leadership team to oversee financial strategy, capital planning, accounting, investor relations, and information technology as the company advances its lead product candidate, MM120, for treating generalized anxiety disorder and major depressive disorder.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.